Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Procalcitonin as a Prognostic Factor in Patients with COVID-19 in Southwestern Iran

Author(s): Milad Shahini Shams Abadi, Elham Taheri, Ahmad Raesi, Mohammad-Hassan Arjmand, Soleiman Kheirii, Najmeh Shahinfard and Zahra Habibi*

Volume 22, Issue 3, 2022

Published on: 01 February, 2022

Article ID: e070122200097 Pages: 5

DOI: 10.2174/1871526522666220107141109

Price: $65

Abstract

Background: There is increasing evidence supporting a central role of the viral-induced hyper-inflammatory immune response in the pathogenesis of COVID-19. Serum procalcitonin (PCT) is an emerging prognostic marker in coronavirus disease 2019 (COVID-19). The aim of this study was to investigate the relationship between serum procalcitonin and clinical severity and outcomes in patients with coronavirus disease 2019 (COVID-19).

Materials and Methods: Hematological and biochemical parameters were evaluated in patients with COVID-19 infection from February to April 2020 at Hajar Hospital in the Shahrekord University of Medical Science, Shahrekord, Iran.

Results: The results showed that total lymphocyte counts, albumin, calcium, and creatinine levels were significantly different between the two moderate and severe groups, and the mean of procalcitonin level in COVID-19 patients with severe disease was higher (0.36 ng/mL) compared with the patients with moderate disease, and its level was found to be >5 ng/mL in 14.2% of5 ng/mL in 14.2% of patients in the former group.

Conclusion: PCT may be a marker of disease severity in COVID-19 and may contribute to determining the severity of patients infected with SARS-CoV-2. Moreover, serial PCT measurements may be beneficial in predicting the prognosis.

Keywords: Procalcitonin, COVID-19, albumin, calcium, creatinine, prognosis.

Graphical Abstract

[1]
Laing AG, Lorenc A, Del Molino Del Barrio I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med 2020; 26(10): 1623-35.
[http://dx.doi.org/10.1038/s41591-020-1038-6] [PMID: 32807934]
[2]
Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020; e3319: e3319.
[http://dx.doi.org/10.1002/dmrr.3319] [PMID: 32233013]
[3]
Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E. Prediction models for diagnosis and prognosis of covid-19: Systematic review and critical appraisal. BMJ 2020; 369.
[4]
Qu R, Ling Y, Zhang YH, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol 2020; 92(9): 1533-41.
[http://dx.doi.org/10.1002/jmv.25767] [PMID: 32181903]
[5]
van Berkel M, Kox M, Frenzel T, Pickkers P, Schouten J. Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times? Crit Care 2020; 24(1): 600.
[http://dx.doi.org/10.1186/s13054-020-03291-w] [PMID: 33023606]
[6]
Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 2020; 111: 102452.
[http://dx.doi.org/10.1016/j.jaut.2020.102452] [PMID: 32291137]
[7]
Shahini Shams Abadi M, Siadat SD, Vaziri F, et al. Distribution and diversity of hmw1A among invasive nontypeable haemophilus influenzae isolates in Iran. Avicenna J Med Biotechnol 2016; 8(2): 99-102.
[PMID: 27141269]
[8]
Zhao Z, Chen A, Hou W, et al. Prediction model and risk scores of ICU admission and mortality in COVID-19. PLoS One 2020; 15(7): e0236618.
[http://dx.doi.org/10.1371/journal.pone.0236618] [PMID: 32730358]
[9]
Heesom L, Rehnberg L, Nasim-Mohi M, et al. Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit. J Glob Antimicrob Resist 2020; 22: 782-4.
[http://dx.doi.org/10.1016/j.jgar.2020.07.017] [PMID: 32717489]
[10]
Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents 2020; 56(2): 106051.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106051] [PMID: 32534186]
[11]
Zhou B, She J, Wang Y, Ma X. Utility of ferritin, procalcitonin, and C-reactive protein in severe patients with 2019 novel coronavirus disease. Research Square 2020.
[http://dx.doi.org/10.21203/rs.3.rs-18079/v1]
[12]
Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis 2020; 14: 1753466620937175.
[http://dx.doi.org/10.1177/1753466620937175] [PMID: 32615866]
[13]
Zhang YY, Li BR, Ning BT. The comparative immunological characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 coronavirus infections. Front Immunol 2020; 11: 2033.
[http://dx.doi.org/10.3389/fimmu.2020.02033] [PMID: 32922406]
[14]
Liya G, Yuguang W, Jian L, et al. Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review. APMIS 2020; 128(6): 423-32.
[http://dx.doi.org/10.1111/apm.13047] [PMID: 32363707]
[15]
Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta 2020; 505: 190-1.
[16]
Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol 2020; 127: 104370.
[http://dx.doi.org/10.1016/j.jcv.2020.104370] [PMID: 32344321]
[17]
Kelly A, Levine MA. Hypocalcemia in the critically ill patient. J Intensive Care Med 2013; 28(3): 166-77.
[http://dx.doi.org/10.1177/0885066611411543] [PMID: 21841146]
[18]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[19]
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[20]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]

Rights & Permissions Print Cite
Article Metrics
13
1
© 2024 Bentham Science Publishers | Privacy Policy